-
Molecular Cancer: An in situ dendritic cell tumor vaccine based on engineered exosomes for breast cancer treatment
Time of Update: 2022-03-04
Combination of cell-free exosome-based TLR3 agonists and ICD inducers provides a powerful and novel development platform for designing dendritic cell vaccines for breast cancer therapyCollectively, HELA-Exos developed in this study improved subsequent tumor-reactive CD8+ T cell responses by promoting in situ type 1 conventional dendritic cell (cDC1) activation in triple-negative breast cancer xenograft mice Demonstrated robust antitumor activity in models and human triple-negative breast cancer organoids .
-
Thorax: Incidence, treatment, and survival of malignant pleural and peritoneal mesothelioma
Time of Update: 2022-03-04
90%Recently, a research article was published in Thorax, an authoritative journal in the field of thoracic diseases, which aimed to review the population-based incidence, treatment and survival of MPM since asbestos was banned in the Netherlands in 1993 .
-
Nature Communications: Unexpected: CRISPR gene editing causes heritable mutations in genome structure
Time of Update: 2022-03-04
Nature Communications CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generationsThe study confirmed that CRISPR-Cas9 gene editing results in unforeseen structural mutations in DNA that can be inherited by the next generation .
-
Transl Lung Cancer Res: Efficacy of second-line docetaxel + ramucirumab in patients with metastatic NSCLC without driver mutation
Time of Update: 2022-03-04
Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation .
Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation .
-
Clinical Colorectal Cancer: Real-world data from the Beijing Cancer Hospital team show that regorafenib and fruquintinib are equally effective in the treatment of metastatic colorectal cancer
Time of Update: 2022-03-04
colorectal cancerPatients with metastatic CRC who received regorafenib or fruquintinib between January 2018 and April 2020 were retrospectively collected, and patients treated between May 2020 and February 2021 were prospectively included .
-
Sci Transl Med: Remove the "sugar coating" of tumor cells, and CAR-T becomes a "cannonball"!
Time of Update: 2022-03-04
By knocking out MGAT5 in pancreatic cancer ( PAC ), they found that N- glycans interfere with immune synapse formation, reduce transcriptional activation, cytokines and cytotoxicity, and protect tumors from CAR-T cell killing .
-
Ann Oncol: Phase III BROCADE3 Study Shows Veliparib (Veliparib) Plus Carboplatin/Paclitaxel After Veliparib Maintenance Therapy Improves Outcomes in Patients With BRCA1/2 Germline Mutated Breast Cancer
Time of Update: 2022-03-04
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
-
Transl Lung Cancer Res: The Huaxi team showed that the use of video-assisted thoracoscopy (VATS) and thoracotomy (OT) for lobectomy and PAA in patients with lung cancer are comparable
Time of Update: 2022-03-04
Studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients .
Studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients .
-
European Radiology: Multiparametric MRI-based radiomics for preoperative prediction of extraluminal vein invasion in rectal cancer
Time of Update: 2022-03-04
He developed and validated a combined model for EMVI assessment with histological , clinical, and imaging features, providing technical support for prognostic prediction in the formulation of individualized treatment regimens for rectal cancer patients .
-
European Radiology: The role of texture features of ADC maps in predicting response to chemoradiotherapy in invasive bladder cancer
Time of Update: 2022-03-04
Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer .
1007/s00330-021-08110-6Koichiro Kimura Soichiro Yoshida Junichi Tsuchiya ,et al Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer 10.
-
Target Oncol: FLAURA China Study Shows First-Line Osimertinib Improves Outcomes of EGFR-mutant NSCLC Patients in Chinese Population Compared with Gefitinib
Time of Update: 2022-03-04
Therefore, the domestic team carried out the FLAURA China study, mainly to evaluate the efficacy of osimertinib compared with the first-generation EGFR-TKIs in the first-line treatment of EGFRm NSCLC patients in the Chinese population .
-
Nanjing Legend Bio has suspended the phase I clinical trial of CAR-T therapy LB1901
Time of Update: 2022-03-04
Nanjing Legend Biotech said recently that the FDA has informed the agency that it has suspended the Phase I trial of its autologous CAR-T therapy LB1901 .
com/story/5499517 https://firstwordpharma.
com/story/5499517 https://firstwordpharma.
-
Front Oncol: Exploring the optimal time point for local radiotherapy in patients with unresectable lung adenocarcinoma
Time of Update: 2022-03-04
Interestingly, for patients with bone metastases, mOS was significantly improved with early RT compared with delayed RT (56.
Interestingly, for patients with bone metastases, mOS was significantly improved with early RT compared with delayed RT (56.
-
Eur Urol Focus: What is the efficacy of nivolumab monotherapy in advanced renal cell carcinoma?
Time of Update: 2022-03-04
Manage ImmunizationRecently, researchers from Germany, published in Eur Urol Focus, conducted the NORA (NivOlumab in Renal cell cArcinoma) non-interventional study (NIS), which aims to obtain real-world data to complement the pivotal CheckMate 025 Clinical trial results .
-
Psychiatry Research: Single people are more likely to develop cancer and have higher mortality after cancer
Time of Update: 2022-03-04
The study showed that loneliness in middle-aged men was associated with an increased risk of cancer, and that single men (unmarried, widowed, divorced) had a higher mortality rate from cancer .
-
Target Oncol: Evaluating the efficacy of second-line osimertinib therapy in real-world patients who met and did not meet AURA3 study criteria
Time of Update: 2022-03-04
This retrospective study included patients with advanced NSCLC who received osimertinib after first-line therapy and were divided into two groups according to the inclusion criteria of the AURA3 trial .
-
iRECIST Criteria for Evaluation of the Response of Immunotherapy in Solid Tumors
Time of Update: 2022-03-04
(3) Using a single objective standard to reflect complex lesions, ignoring changes in tumor burden, which often best reflects the quality of life and survival time of patients .
-
Eur Arch Otorhinolaryngol: Long-term Hearing Follow-up of Pediatric Platinum-Induced Ototoxicity
Time of Update: 2022-03-04
Recently, researchers from Italy published an article in "Eur Arch Otorhinolaryngol" on long-term hearing follow-up of platinum-induced ototoxicity in children .
Researchers from Italy, published in Eur Arch Otorhinolaryngol, conducted long-term hearing follow-up of pediatric platinum-induced ototoxicity Hearing follow-upThe study was a retrospective observational design .
-
IJMI: The screening accuracy rate is as high as 92.1%!
Time of Update: 2022-03-04
A research team from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences proposed a non-invasive screening method for cervical lesions based on transmembrane fusion cytology, HPV detection and colposcopy image examination results.
-
Transl Lung Cancer Res: The efficacy of pembrolizumab (pembrolizumab) alone or in combination in the treatment of patients with advanced non-small cell lung cancer with bone metastases
Time of Update: 2022-03-04
30-40% of Shanghai Chest Hospital affiliated to Shanghai Jiaotong University and multi-center conducted a retrospective study to evaluate the efficacy of pembrolizumab (pembrolizumab) alone or in combination in the treatment of patients with advanced non-small cell lung cancer with bone metastases .